Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, confirms that its partner for the Chinese market, Sinophi Healthcare Limited, has recently signed a Framework Agreement with China-Japan Union Hospital of Jilin University in relation to a proton therapy centre.
Advanced Oncotherapy confirms that this Framework Agreement does not as yet constitute a purchase order for a LIGHT machine, but should a purchase order be received by the Company it will notify shareholders in accordance with AIM disclosure rules.
|
Advanced Oncotherapy Plc |
|
|
Sanjeev Pandya, CEO |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CFO |
|
|
|
|
|
Westhouse Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
|
|
|
Beaufort Securities (Joint Broker) |
|
|
Jon Levinson / Zoe Alexander |
Tel: +44 20 7382 8300 |
|
|
|
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |